TY - STD TI - Rosenbloom BE, Weinreb NJ. Gaucher disease: a comprehensive review. Crit Rev Oncog. 2013;18:163–75. doi:10.1615/CritRevOncog.2013006060. ID - ref1 ER - TY - STD TI - Burrow TA, Barnes S, Grabowski GA. Prevalence and management of Gaucher disease. Pediatric Health Med Ther. 2011;2:59–73. doi:10.2147/PHMT.S12499. ID - ref2 ER - TY - JOUR AU - Bennett, L. L. AU - Mohan, D. PY - 2013 DA - 2013// TI - Gaucher disease and its treatment options JO - Ann Pharmacother VL - 47 UR - https://doi.org/10.1177/1060028013500469 DO - 10.1177/1060028013500469 ID - Bennett2013 ER - TY - STD TI - Deegan PB, Batista J. Risk factors for fracture in imiglucerase-treated Gaucher disease type 1 patients in the ICGG Gaucher Registry. Mol Genet Metab. 2016;117(2):S40. doi:10.1016/j.ymgme.2015.12.237. ID - ref4 ER - TY - CHAP AU - Grabowski, G. A. AU - Petsko, G. A. AU - Kolodny, E. H. PY - 2007 DA - 2007// TI - Gaucher disease BT - The online metabolic and molecular bases of inherited disease PB - McGraw-Hill CY - New York ID - Grabowski2007 ER - TY - JOUR AU - Martins, A. M. AU - Valadares, E. R. AU - Porta, G. AU - Coelho, J. AU - Semionato Filho, J. AU - Pianovski, M. A. AU - Kerstenetzky, M. S. AU - Montoril Mde, F. AU - Aranda, P. C. AU - Pires, R. F. PY - 2009 DA - 2009// TI - Recommendations on diagnosis, treatment, and monitoring for Gaucher disease JO - J Pediatr VL - 155 UR - https://doi.org/10.1016/j.jpeds.2009.07.004 DO - 10.1016/j.jpeds.2009.07.004 ID - Martins2009 ER - TY - JOUR AU - Balwani, M. AU - Burrow, T. A. AU - Charrow, J. AU - Goker-Alpan, O. AU - Kaplan, P. AU - Kishnani, P. S. AU - Mistry, P. AU - Ruskin, J. AU - Weinreb, N. PY - 2016 DA - 2016// TI - Recommendations for the use of eliglustat in the treatment of adults with Gaucher disease type 1 in the United States JO - Mol Genet Metab VL - 117 UR - https://doi.org/10.1016/j.ymgme.2015.09.002 DO - 10.1016/j.ymgme.2015.09.002 ID - Balwani2016 ER - TY - JOUR AU - Dussen, L. AU - Biegstraaten, M. AU - Hollak, C. E. AU - Dijkgraaf, M. G. PY - 2014 DA - 2014// TI - Cost-effectiveness of enzyme replacement therapy for type 1 Gaucher disease JO - Orphanet J Rare Dis VL - 9 UR - https://doi.org/10.1186/1750-1172-9-51 DO - 10.1186/1750-1172-9-51 ID - Dussen2014 ER - TY - STD TI - Ficicioglu C. Review of miglustat for clinical management in Gaucher disease type 1. Ther Clin Risk Manag. 2008;4(2):425–31. doi:10.2147/TCRM.S6865. ID - ref9 ER - TY - STD TI - Connock M, Burls A, Frew E, Fry-Smith A, Juarez-Garcia A, McCabe C, Wailoo A, Abrams K, Cooper N, Sutton A, et al. The clinical effectiveness and cost-effectiveness of enzyme replacement therapy for Gaucher's disease: a systematic review. Health Technol Assess. 2006;10(24):iii-iv, ix-136. https://www.ncbi.nlm.nih.gov/books/NBK62295. Accessed 13 Feb 2017. UR - https://www.ncbi.nlm.nih.gov/books/NBK62295/ ID - ref10 ER - TY - JOUR AU - Weinreb, N. J. AU - Cappellini, M. D. AU - Cox, T. M. AU - Giannini, E. H. AU - Grabowski, G. A. AU - Hwu, W. L. AU - Mankin, H. AU - Martins, A. M. AU - Sawyer, C. AU - vom Dahl, S. PY - 2010 DA - 2010// TI - A validated disease severity scoring system for adults with type 1 Gaucher disease JO - Genet Med VL - 12 UR - https://doi.org/10.1097/GIM.0b013e3181c39194 DO - 10.1097/GIM.0b013e3181c39194 ID - Weinreb2010 ER - TY - JOUR AU - Weinreb, N. J. AU - Finegold, D. N. AU - Feingold, E. AU - Zeng, Z. AU - Rosenbloom, B. E. AU - Shankar, S. P. AU - Amato, D. PY - 2015 DA - 2015// TI - Evaluation of disease burden and response to treatment in adults with type 1 Gaucher disease using a validated disease severity scoring system (DS3) JO - Orphanet J Rare Dis VL - 10 UR - https://doi.org/10.1186/s13023-015-0280-3 DO - 10.1186/s13023-015-0280-3 ID - Weinreb2015 ER - TY - STD TI - Busner J, Targum SD. The clinical global impressions scale: applying a research tool in clinical practice. Psychiatry (Edgmont). 2007;4(7):28–37. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2880930. Accessed 13 Feb 2017. UR - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2880930 ID - ref13 ER - TY - JOUR AU - Zimran, A. AU - Sorge, J. AU - Gross, E. AU - Kubitz, M. AU - West, C. AU - Beutler, E. PY - 1989 DA - 1989// TI - Prediction of severity of Gaucher's disease by identification of mutations at DNA level JO - Lancet VL - 334 UR - https://doi.org/10.1016/S0140-6736(89)90536-9 DO - 10.1016/S0140-6736(89)90536-9 ID - Zimran1989 ER - TY - BOOK AU - Ware, J. E. AU - Snow, K. K. AU - Kosinski, M. AU - Gandek, B. PY - 1993 DA - 1993// TI - SF-36 health survey: manual and interpretation guide PB - The Health Institute, New England Medical Center Hospital CY - Boston ID - Ware1993 ER - TY - JOUR AU - Brooks, R. PY - 1996 DA - 1996// TI - EuroQol: the current state of play JO - Health Policy VL - 37 UR - https://doi.org/10.1016/0168-8510(96)00822-6 DO - 10.1016/0168-8510(96)00822-6 ID - Brooks1996 ER - TY - STD TI - Brazier JE, Roberts J. The estimation of a preference-based measure of health from the SF-12. Med Care. 2004;42(9):851–9. http://www.jstor.org/stable/4640827. Accessed 13 Feb 2017. UR - http://www.jstor.org/stable/4640827 ID - ref17 ER - TY - JOUR AU - Kleinman, L. C. AU - Norton, E. C. PY - 2009 DA - 2009// TI - What’s the risk? a simple approach for estimating adjusted risk measures from nonlinear models including logistic regression JO - Health Serv Res VL - 44 UR - https://doi.org/10.1111/j.1475-6773.2008.00900.x DO - 10.1111/j.1475-6773.2008.00900.x ID - Kleinman2009 ER - TY - JOUR AU - Weinreb, N. J. AU - Goldblatt, J. AU - Villalobos, J. AU - Charrow, J. AU - Cole, J. A. AU - Kerstenetzky, M. AU - vom Dahl, S. AU - Hollak, C. PY - 2013 DA - 2013// TI - Long-term clinical outcomes in type 1 Gaucher disease following 10 years of imiglucerase treatment JO - J Inherit Metab Dis VL - 36 UR - https://doi.org/10.1007/s10545-012-9528-4 DO - 10.1007/s10545-012-9528-4 ID - Weinreb2013 ER - TY - JOUR AU - Zimran, A. AU - Wang, N. AU - Ogg, C. AU - Crombez, E. AU - Cohn, G. M. AU - Elstein, D. PY - 2015 DA - 2015// TI - Seven-year safety and efficacy with velaglucerase alfa for treatment-naive adult patients with type 1 Gaucher disease JO - Am J Hematol VL - 90 UR - https://doi.org/10.1002/ajh.24040 DO - 10.1002/ajh.24040 ID - Zimran2015 ER - TY - STD TI - Weinreb NJ, Rosenbloom BE. Splenomegaly, hypersplenism, and hereditary disorders with splenomegaly. Open J Genetics. 2013;3:24–43. doi:10.4236/ojgen.2013.31004. ID - ref21 ER - TY - JOUR AU - Weinreb, N. J. AU - Deegan, P. AU - Kacena, K. A. AU - Mistry, P. AU - Pastores, G. M. AU - Velentgas, P. AU - vom Dahl, S. PY - 2008 DA - 2008// TI - Life expectancy in Gaucher disease type 1 JO - Am J Hematol VL - 83 UR - https://doi.org/10.1002/ajh.21305 DO - 10.1002/ajh.21305 ID - Weinreb2008 ER - TY - JOUR AU - Mistry, P. K. AU - Lukina, E. AU - Ben Turkia, H. AU - Amato, D. AU - Baris, H. AU - Dasouki, M. AU - Ghosn, M. AU - Mehta, A. AU - Packman, S. AU - Pastores, G. PY - 2015 DA - 2015// TI - Effect of oral eliglustat on splenomegaly in patients with Gaucher disease type 1: the ENGAGE randomized clinical trial JO - JAMA VL - 313 UR - https://doi.org/10.1001/jama.2015.459 DO - 10.1001/jama.2015.459 ID - Mistry2015 ER - TY - STD TI - Giraldo P, Solano V, Perez-Calvo JI, Giralt M, Rubio-Felix D. Spanish group on gaucher d. Quality of life related to type 1 gaucher disease: Spanish experience. Qual Life Res. 2005;14(2):453–62. http://www.jstor.org/stable/4038778. Accessed 13 Feb 2017. UR - http://www.jstor.org/stable/4038778 ID - ref24 ER - TY - JOUR AU - Weinreb, N. AU - Barranger, J. AU - Packman, S. AU - Prakash-Cheng, A. AU - Rosenbloom, B. AU - Sims, K. AU - Angell, J. AU - Skrinar, A. AU - Pastores, G. M. PY - 2007 DA - 2007// TI - Imiglucerase (Cerezyme) improves quality of life in patients with skeletal manifestations of gaucher disease JO - Clin Genet VL - 71 UR - https://doi.org/10.1111/j.1399-0004.2007.00811.x DO - 10.1111/j.1399-0004.2007.00811.x ID - Weinreb2007 ER - TY - CHAP AU - Janssen, B. AU - Szende, A. PY - 2013 DA - 2013// TI - Population norms for the EQ-5D BT - Self-reported population health: an international perspective based on EQ-5D PB - Springer Netherlands CY - Dordrecht ID - Janssen2013 ER - TY - JOUR AU - Charrow, J. AU - Scott, C. R. PY - 2015 DA - 2015// TI - Long-term treatment outcomes in Gaucher disease JO - Am J Hematol VL - 90 UR - https://doi.org/10.1002/ajh.24056 DO - 10.1002/ajh.24056 ID - Charrow2015 ER - TY - JOUR AU - Deegan, P. B. AU - Pavlova, E. AU - Tindall, J. AU - Stein, P. E. AU - Bearcroft, P. AU - Mehta, A. AU - Hughes, D. AU - Wraith, J. E. AU - Cox, T. M. PY - 2011 DA - 2011// TI - Osseous manifestations of adult Gaucher disease in the era of enzyme replacement therapy JO - Medicine (Baltimore) VL - 90 UR - https://doi.org/10.1097/MD.0b013e3182057be4 DO - 10.1097/MD.0b013e3182057be4 ID - Deegan2011 ER - TY - JOUR AU - Anderson, L. J. AU - Henley, W. AU - Wyatt, K. M. AU - Nikolaou, V. AU - Hughes, D. A. AU - Waldek, S. AU - Logan, S. PY - 2014 DA - 2014// TI - Long-term effectiveness of enzyme replacement therapy in adults with Gaucher disease: results from the NCS-LSD cohort study JO - J Inherit Metab Dis VL - 37 UR - https://doi.org/10.1007/s10545-014-9680-0 DO - 10.1007/s10545-014-9680-0 ID - Anderson2014 ER - TY - JOUR AU - Anderson, L. J. AU - Henley, W. AU - Wyatt, K. M. AU - Nikolaou, V. AU - Waldek, S. AU - Hughes, D. A. AU - Pastores, G. M. AU - Logan, S. PY - 2014 DA - 2014// TI - Long-term effectiveness of enzyme replacement therapy in children with Gaucher disease: results from the NCS-LSD cohort study JO - J Inherit Metab Dis VL - 37 UR - https://doi.org/10.1007/s10545-014-9693-8 DO - 10.1007/s10545-014-9693-8 ID - Anderson2014 ER - TY - JOUR AU - Hollak, C. E. AU - Weinreb, N. J. PY - 2015 DA - 2015// TI - The attenuated/late onset lysosomal storage disorders: Therapeutic goals and indications for enzyme replacement treatment in Gaucher and Fabry disease JO - Best Pract Res Clin Endocrinol Metab VL - 29 UR - https://doi.org/10.1016/j.beem.2014.08.006 DO - 10.1016/j.beem.2014.08.006 ID - Hollak2015 ER - TY - JOUR AU - Weinreb, N. AU - Taylor, J. AU - Cox, T. AU - Yee, J. AU - vom Dahl, S. PY - 2008 DA - 2008// TI - A benchmark analysis of the achievement of therapeutic goals for type 1 Gaucher disease patients treated with imiglucerase JO - Am J Hematol VL - 83 UR - https://doi.org/10.1002/ajh.21280 DO - 10.1002/ajh.21280 ID - Weinreb2008 ER - TY - JOUR AU - Rocco, M. AU - Giona, F. AU - Carubbi, F. AU - Linari, S. AU - Minichilli, F. AU - Brady, R. O. AU - Mariani, G. AU - Cappellini, M. D. PY - 2008 DA - 2008// TI - A new severity score index for phenotypic classification and evaluation of responses to treatment in type I Gaucher disease JO - Haematologica VL - 93 UR - https://doi.org/10.3324/haematol.12379 DO - 10.3324/haematol.12379 ID - Rocco2008 ER - TY - STD TI - Burrow TA, Balwani M, Cox TM, Drelichman G, Cravo R, Martins AM, Lukina E, Rosenbloom BE, Ross LH, Angell J, Puga AC. ENCORE: A randomized, controlled, open-label non-inferiority study comparing eliglustat to imiglucerase in gaucher disease type 1 patients on enzyme replacement therapy who have reached therapeutic goals. Blood. 2013;122(21):3468. http://www.bloodjournal.org/content/122/21/3468. Accessed 13 Feb 2017. UR - http://www.bloodjournal.org/content/122/21/3468 ID - ref34 ER - TY - JOUR AU - Cox, T. M. AU - Drelichman, G. AU - Cravo, R. AU - Balwani, M. AU - Burrow, T. A. AU - Martins, A. M. AU - Lukina, E. AU - Rosenbloom, B. AU - Ross, L. AU - Angell, J. AU - Puga, A. C. PY - 2015 DA - 2015// TI - Eliglustat compared with imiglucerase in patients with Gaucher’s disease type 1 stabilised on enzyme replacement therapy: a phase 3, randomised, open-label, non-inferiority trial JO - Lancet VL - 385 UR - https://doi.org/10.1016/S0140-6736(14)61841-9 DO - 10.1016/S0140-6736(14)61841-9 ID - Cox2015 ER -